Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Thu, 13.03.2025
cyan AG
cyan AG achieves guidance for the 2024 financial year and plans further strong corporate growth
Consolidated operating sales of EUR 7.1 million achieved
Growth target of 50 % achieved compared to the previous year
Significant improvement in EBITDA to EUR -1.6 to -1.5 million
Investments in development and sales planned for further growth
Munic [ … ]
Thu, 13.03.2025
MLP SE
FY 2024: Earnings at upper end of forecast, revenue above one billion euros for the first time – significant growth planned up to 2028
FY 2024: Total revenue increased on a very broad basis and for the eleventh year in succession, new all-time high of EUR 1,067 million (plus 10 percent) achieved, compound annual growth rate (CAGR) of 9 percent sin [ … ]
Thu, 13.03.2025
Hannover Rück SE
Hannover Re significantly increases dividend after a highly successful 2024 financial year
Group net income rises by 28% to EUR 2.3 billion and reaches guidance, which had been revised higher in autumn 2024
Return on equity increases to 21.2% and clearly exceeds strategic target
Reinsurance revenue increases by 7.9% to EUR 26.4 billion
Opera [ … ]
Thu, 13.03.2025
Masterflex SE
Masterflex SE achieves record operating result in financial year 2024 according to preliminary figures
Consolidated sales revenue of EUR 98.1 million according to preliminary figures (previous year: EUR 101.1 million)
Record EBITDA of EUR 18.2 million (previous year: EUR 17.9 million) and operating EBIT of EUR 12.7 million (previous year: EUR 12. [ … ]
Thu, 13.03.2025
Heidelberg Pharma AG
PRESS RELEASE
Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
HealthCare Royalty and Heidelberg Pharma amend royalty financing agreement to provide for USD 20 million payment
Heidelberg Pharma extends cash runway into 2027
Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company [ … ]
Thu, 13.03.2025
grenke AG
grenke generates a EUR 70.2 million profit in 2024 and maintains growth trajectory
Group earnings 2024 reach EUR 70.2 million (2023: EUR 86.7 million)
Proposed dividend of EUR 0.40 per share (2023: EUR 0.47)
Guidance for 2025: Leasing new business between EUR 3.2 and EUR 3.4 billion and Group earnings in the range of EUR 71 to 81 million
Bade [ … ]
Thu, 13.03.2025
INFICON Holding AG
Corporate ContactMatthias TröndleChief Financial Officer+423 388 3510 matthias.troendle@inficon.com'Ad hoc announcement pursuant to Art. 53 LR'
Announcement of INFICON Holding AGBad Ragaz/Switzerland, March 13, 2025
Fourth Quarter 2024: Record sales USD 177.5 million, plus 1.7% over prior year and 3.1% over Q3 2024; Operating profit USD 36.1 mi [ … ]
Thu, 13.03.2025
Swiss Re Ltd
Ad hoc announcement pursuant to Article 53 LR
Swiss Re maintains a strong capital position; Group Swiss Solvency Test (SST) ratio of 257% as of 1 January 2025[1]
Swiss Re proposes to elect Morten Hübbe and George Quinn as new members of the Board of Directors; Philip Ryan and Sir Paul Tucker will not stand for re-election
Swiss Re publishes Annu [ … ]
Thu, 13.03.2025
HELLA GmbH & Co. KGaA
LIPPSTADT (GERMANY)
13 March 2025
Fiscal Year 2024: FORVIA HELLA achieves solid financial results in a challenging industry environment
Currency-adjusted sales improve by 1.3 percent to €8.1 billion; reported sales of €8.0 billion remains at the previous year's level
Operating income falls to €446 million, among others due to underutiliza [ … ]
Thu, 13.03.2025
Nyxoah SA.
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results
FDA PMA Application Review Nearing Conclusion
Positioned for U.S. Commercial Launch in the First Quarter 2025
Mont-Saint-Guibert, Belgium – March 13, 2025, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that dev [ … ]